Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction

Congestive Heart Failure Clinical Trial

Official title:

Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02292043
• Other study ID #: wei liu
• Status: Recruiting
• Phase: N/A
• First received: October 31, 2014
• Last updated: November 12, 2014
• Start date: May 2013
• Est. completion date: January 2015

Study information

• Verified date: November 2014
• Source: Harbin Medical University
• Contact: wei liu, Ph.D.
• Phone: 86-18904502999
• Is FDA regulated: No
• Health authority: China: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction.

Description:

The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction. The specific index is 6 miniutes walk distance, echocardiography, NYHA, NTproBNP level, peripherial WBC, RBC, PLT, Cre, UA, K+, Na+ upon entrance to hospital and 4 weeks after HTEA treatment, and 3 months after discharge. The morbidity and re-hospitalization would also calculated 3 months after discharge.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: January 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• 90 chronic cardiac failure patients in our hospital were selected and divided into two groups.

Exclusion Criteria:

• Vavular diseases

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Dilated
• Congestive Heart Failure
• Heart Failure
• Myocardial Infarction

Intervention

Drug:
• HTEA
HTEA

Locations

Country	Name	City	State
China	Ren Xiaohui	Harbin	Heilongjiang
China	the first affiliated hospital of Harbin Medical University	Harbin	Heilongjiang

Sponsors (1)

Lead Sponsor	Collaborator
Harbin Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Morbidity		1 months to 3 months after discharge	No
Secondary	The decreased degree of NT-proBNP higher than 30%		3 months after discharge	No